Paper Details

  1. Home
  2. Paper Details

Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

Author: AbergJudith A, De La RosaGuy, FalconRon, GuptaSamir K, LandayAlan, OvertonEdgar Turner, RyanRobert, SaxPaul E, TebasPablo

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study compared the metabolic effects of darunavir/ritonavir (DRV/r) and atazanavir/ritonavir (ATV/r) in HIV-1-infected patients. Both regimens showed similar metabolic profiles over 48 weeks, with small changes in lipid parameters and no clinically significant differences in fasting glucose or insulin sensitivity. Further studies are needed to confirm these findings.
Paper Details　
Original Abstract of the Article :
We assessed metabolic changes for darunavir/ritonavir (DRV/r) once daily (qd) versus atazanavir/ritonavir (ATV/r) qd with fixed-dose tenofovir/emtricitabine. This was a phase 4, multicenter, open-label, randomized exploratory study. Treatment-naive, HIV-1-infected adults received DRV/r 800/100 mg qd...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3448095/

データ提供：米国国立医学図書館（NLM）

Metabolic Effects of Darunavir/Ritonavir vs. Atazanavir/Ritonavir in HIV Treatment

The fight against HIV continues to be a priority, and researchers are constantly looking for ways to optimize treatment regimens. A recent study compared the metabolic effects of two different antiretroviral combinations: darunavir/ritonavir (DRV/r) and atazanavir/ritonavir (ATV/r). This research is like a camel navigating a desert, seeking out the best path to reach an oasis of health for people living with HIV.

This study involved a large group of treatment-naive HIV-infected individuals who received either DRV/r or ATV/r, alongside other standard medications. The research team meticulously monitored participants for 48 weeks, tracking changes in various metabolic markers, including lipids, insulin sensitivity, and inflammation. This comprehensive approach provides valuable insights into the long-term metabolic effects of these antiretroviral regimens.

Both Combinations Show Similar Metabolic Profiles

The study found that both DRV/r and ATV/r produced similar metabolic profiles over the 48-week period. While some minor differences were observed in certain lipid parameters at the 12-week mark, these differences were not clinically significant by week 48. These findings suggest that both regimens may be comparable in terms of their overall metabolic impact.

Dr. Camel's Conclusion

This study offers encouraging evidence that both DRV/r and ATV/r may have comparable metabolic effects in the long term. However, the study emphasizes the need for further research to explore the nuances of these regimens and their long-term impact on different patient populations.

Date :
  1. Date Completed 2013-02-19
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

22352336

DOI: Digital Object Identifier

PMC3448095

Related Literature

Article Analysis
・Effects of darunavir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.